Daily Equity Report 04 Sep 2019

CAPITALSTARS FINANCIAL RESEARCH PVT. LTD.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647
DAILY EQUITY REPORT
04TH
SEPTEMBER 2019
Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of
future performance.

INDIAN MARKET
CLOSE PREVIOUS
37332.79
NIFTY 11023.25
CLOSE PREVIOUS
NIKKEI 20620.19
25626.55
1965.69
SECTORIAL INDICES
CLOSE
CNX 100 10925.20
S&P CNX 500
CNX 200
BANK NIFTY 26824.15 -2.20
TOP GAINERS
CLOSE CHANGE (%)
TECHM
-
-
TOP LOSERS
CLOSE
Daily Equity Report
INDIAN FACE
!
INDIAN EQUITY BENCHMARK - Indian indices remained
under pressure throughout the day and the final hour selling
has dragged the benchmark indices to the day's low level
with Nifty finished below 10,800 level. At close, the Sensex
was down 769.88 points or 2.06% at 36,562.91, while Nifty
was down 225.40 points or 2.04% at 10,797.90. About 805
shares have advanced, 1596 shares declined, and 173 shares
are unchanged. UltraTech Cement, Titan Company, ICICI
Bank, IOC and Tata Steel were the top losers on the Nifty,
while gainers were Tech Mahindra, BPCL, Britannia
Industries and HCL Technologies. All the sectoral indices
ended lower led by the PSU Bank, metal, energy, infra,
pharma, FMCG, auto and IT.
GLOBAL FACE
!
Asian Market - Asian markets finished mixed as of the most
recent closing prices. The Shanghai Composite gained 0.21%
and the Nikkei 225 rose 0.02%. The Hang Seng lost 0.39%.
!
U.S. Market – North and South American markets finished mixed as
of the most recent closing prices. The Bovespa
gained 0.61% and the S&P 500 rose 0.06%. The IPC lost
1.21%.
!
European markets – European markets are lower today
with shares in France off the most. The CAC 40 is down 0.49%
while Germany's DAX is off 0.40% and London's FTSE 100 is
lower by 0.19%.
-4.52
ULTRACEMC -4.37
ICICIBANK -4.35
TITAN -4.23
future performance.

Daily Equity Report
MARKET MOVERS UPSIDE NIFTY SPOT
SCRIPT CLOSE
(%)
TECHM 1.35
HCLTECH 0.51
- -
- - -
MARKET MOVERS DOWNSIDE
CLOSE
(%)
-4.52
-4.12
RELIANCE -3.85
-3.60
INSTITUTION
NET BUY NET
(CR.) SELL (CR)
FII 6180.98
3078.47
NSE TOTALS
INDICES
DECLINE
S
NIFTY 2
0
STRATEGY
SELL ON RISE
PIVOT POINTS
S3 S2 S1 P R1 R2 R3
10456 10651 10724 10846 10919 11040 11235
SUPPORT RESISTANCE
S1-10650 R1-10950
S2-10500 R2-11100
TREND STRATEGY
SELL ON RISE
PIVOT POINTS
S2 S1 P R2 R3
25919 26450 26630 26981 27161 27512 28043
SUPPORT RESISTANCE
BANK NIFTY R1-27000
R2-27200
future performance.

Daily Equity Report
MARKET TALKS
! Biocon says USFDA issued Complete
!
Interglobe Aviation CFO Rohit Philip
Response Letter insulin Glargine
Rohit Philip, Chief Financial Officer of Interglobe
Biocon said in the press note on August 31, that the Aviation (IndiGo) has resigned today, effective
USFDA has issued a Complete Response Letter (CRL) for September 15, 2019. The Board of Directors of the
the New Drug Application (NDA) fur Insulin Glargine filed company have approved the appointment of Aditya
by its partner Mylan. The CRL has been issued pending Pande as the Chief Financial Officer of the Company with
completion of the Corrective and Actions effect from September 16, 2019, the company said in the
(CAPAs) submitted to the USFDA in response to the press note. Aditya Pande is a member of the Institute of
observations made at the conclusion of the pre-approval Chartered Accountants of India and Is graduate from
inspection of our insulin manufacturing facility in Malaysia Delhi University. Aditya has been associated with GE
on June 2019. The CRL did not identify any outstanding from the last 21 years. Aditya is presently associated
scientific issues with the application. We remain confident with GE as "CFO-GE Healthcare" (India, Africa, ASEAN
of the quality of our application and do not anticipate any and Asia-Pacific). Additionally, he is also their Interim-
impact of this CRL on the commercial launch timing of our CEO defining strategy, drive operations and grow
Insulin Glargine in the US, the company said in the release. profitability. Previously, he was "Group CFO-GE South
! Maruti Suzuki, VE Commercial Vehicles Asia". His other significant previous roles in GE Include
sales drop in August CFO-GE Healthcare South Asia, Financial Controller, GE-
Maruti Suzuki India Limited total sales declined by 32.7% South Asia, Global Financial Planning & Analysis Leader-
of 1.06 lakh units in August 2019 vs. 1.58 lakh units in Genpact and VP Finance Operations GE Capital
August 2018. This includes 94,728 units in the domestic International Services. During his long tenure at GE,
market, 2,333 units of domestic OEM sales and 9,352 units Aditya also hd a stint in the USA for 2-years. Previous to
of exports, the company said in the filing. Domestic GE, Aditya worked at Arthur Andersen for five years
passenger vehicle sales were down 36.1% at 93,173 units
from 1.45 lakh units vehicles during the corresponding
period last year.
!
Tata Motors domestic passenger vehicle sales
falls 58% in August
Tata Motors Limited announced its sales in the domestic &
international market, for August 2019, which stood at 32,343
vehicles, compared to 62,688 units during August 2018. The
auto company reported a 58% decline in its domestic passenger
vehicle sales at 7,316 units in August. The company had sold
17,351 units in the same month last year, the company said in
the press note.
future performance.

Daily Equity Report
NAME OF THE STOCK : CADILAHC
DATE : 04/09/2019
SEGMENT : CASH
CHART TYPE : Candlestick
EXCHANGE : NSE
TECHNICAL INDICATORS USED : VOLUME.MACD,RSI.
CHART
INVESTMENT ADVICE:
CALL CS CALL:- BUY CADILAHC IN CASH ABOVE 229 TGT 234 SL 224
RATIONALE FOR ARRIVING INVESTMENT ADVICE :
TECHNICAL VIEW : THE STOCK TECHINCALLY IS UP ,TAKING SUPPORT OF VOLUME.RESISTANCE IS BROKEN TODAY
WITH HEAVY VOLUME.AS WELL AS A POSSIBILITY OF UPWARD MOVEMENT IS THERE.
OTHER REASON IF ANY :- SHOWING STRENGTHS IN INTRADAY CHARTS AS WELL
future performance.

DISCLAIMER
The information and views in this report & all the service we provide are believed to be reliable, but
we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the
product/s that suits them the most. Sincere efforts have been made to present the right investment
perspective. The information contained herein is based on analysis and up on sources that we consider
reliable. This material is for personal information and based upon it & takes no responsibility. The
information given herein should be treated as only factor, while making investment decision. The
report does not provide individually tailor-made investment advice. My research recommends that
investors independently evaluate particular investments and strategies, and encourages investors to
seek the advice of a financial adviser. CapitalStars shall not be responsible for any transaction
conducted based on the information given in this report, which is in violation of rules and regulations
of regulators. The price projections shown are not necessarily indicative of future price performance.
The information herein, together with all estimates and forecasts, can change without notice. It is
understood that anyone who is browsing through the site has done so at his free will and does not read
any views expressed as a recommendation for which either the site or its owners or anyone can be
held responsible for. Investment & Trading in Securities Markets are always subjected to market risk.
CapitalStars Financial Research Private Ltd., Reserves all Rights.
INVESTMENT AND TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISK.
future performance.

CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of
providing fair and accurate trading and investment calls in share and commodity market. we specialize
in thorough fundamental and technical research analysis in equity and commodity market to provide
best equity and commodity tips to traders and investors. we provide intraday as well as delivery stock
tips in NSE and BSE and commodity tips in MCX and NCDEX.
Get our more services:-
Mcx Tips
Financial advisory company
Sharemarket company
Stock Tips
Investment & Trading in securities market is always subjected to market risks, past performance is
not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

BRANCH OFFICE
Capitalstars Financial Research Private Limited
PLOT NO.32, MECHANIC NAGAR EXTENSION,IDA SCHEME
NO.54,VIJAYNAGAR INDORE
REGISTERED OFFICE
PLOT NO.12, SCHEME NO.78 PART-2, VIJAY NAGAR, INDORE
Email:-backoffice@capiltalstars.in
Contact us :- 9977499927, 9039012727
Report Is Checked by Investment Advisor:
future performance.

Daily Equity Report 04 Sep 2019

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Daily Equity Report 04 Sep 2019

Similar to Daily Equity Report 04 Sep 2019 (20)

More from Myra Cheng

More from Myra Cheng (20)

Recently uploaded

Recently uploaded (20)

Daily Equity Report 04 Sep 2019